- Home
- STTK vs INBX Comparison
STTK vs INBX Comparison
Compare STTK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- INBX
- Stock Information
- Founded
- STTK 2016
- INBX 2010
- Country
- STTK United States
- INBX United States
- Employees
- STTK N/A
- INBX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- INBX Health Care
- Exchange
- STTK Nasdaq
- INBX Nasdaq
- Market Cap
- STTK 173.6M
- INBX 232.2M
- IPO Year
- STTK 2020
- INBX 2020
- Fundamental
- Price
- STTK $3.86
- INBX $15.18
- Analyst Decision
- STTK Strong Buy
- INBX Hold
- Analyst Count
- STTK 3
- INBX 1
- Target Price
- STTK $10.67
- INBX N/A
- AVG Volume (30 Days)
- STTK 150.7K
- INBX 101.8K
- Earning Date
- STTK 11-07-2024
- INBX 08-13-2024
- Dividend Yield
- STTK N/A
- INBX N/A
- EPS Growth
- STTK N/A
- INBX N/A
- EPS
- STTK N/A
- INBX 118.83
- Revenue
- STTK $4,123,999.00
- INBX $1,687,000.00
- Revenue This Year
- STTK $164.45
- INBX N/A
- Revenue Next Year
- STTK N/A
- INBX N/A
- P/E Ratio
- STTK N/A
- INBX $0.13
- Revenue Growth
- STTK 380.09
- INBX 24.26
- 52 Week Low
- STTK $1.33
- INBX $10.80
- 52 Week High
- STTK $11.76
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- STTK 57.18
- INBX 61.15
- Support Level
- STTK $3.37
- INBX $15.01
- Resistance Level
- STTK $3.75
- INBX $16.34
- Average True Range (ATR)
- STTK 0.24
- INBX 0.74
- MACD
- STTK 0.08
- INBX 0.21
- Stochastic Oscillator
- STTK 88.57
- INBX 65.62
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.